Gemcitabine - Eli Lilly/Genentech

Drug Profile

Gemcitabine - Eli Lilly/Genentech

Alternative Names: dFdC; dFdCTP; Gemtro; Gemzar; LY 188011

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly; Genentech; University of Innsbruck
  • Developer Cancer Research UK; Eli Lilly; Genentech; Mayo Clinic; National Cancer Institute (USA); University of Iowa
  • Class Antineoplastics; Deoxyribonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Biliary cancer; Bladder cancer; Breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer
  • Phase III Cervical cancer
  • Phase II Lymphoma; Renal cell carcinoma; Salivary gland cancer
  • Phase I/II Sarcoma
  • No development reported Head and neck cancer; Solid tumours

Most Recent Events

  • 17 Nov 2017 Roche plans a phase I/II trial for Non-small cell lung cancer (Combination therapy, Metastatic disease) in Australia, South Korea, France, Spain, United Kingdom and USA in December 2017 (NCT03337698)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer in Germany (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Head-and-neck-cancer in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top